Drug Profile
Research programme: Parkinson's disease therapies - Elan
Alternative Names: PLK inhibitors - ElanLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Elan Pharmaceuticals
- Class
- Mechanism of Action Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Parkinson's-disease in USA